Skip to main content

Advertisement

SpringerLink
Log in

New targeted therapies in gastrointestinal cancers

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Despite surgical, radiotherapeutic, and chemotherapeutic advances, a large proportion of gastrointestinal (GI) cancers remain incurable. An improved understanding of the molecular pathogenesis of cancer has promulgated the development of novel agents designed to target critical pathways involved in cancer development and progression. The crucial role of the epidermal growth factor receptor (EGFR) in tumor proliferation and the overexpression of EGFR in several GI cancers provides the rationale for targeting and interrupting this key signaling network. EGFR blockade through monoclonal antibodies (C225 and ABX-EGF) and tyrosine kinase inhibitors (ZD1839 and OSI-774) has translated into promising evidence of clinical benefit. Ras-mediated signal transduction has been targeted using inhibitors of farnesyl transferase (R115777 and SCH66336) to block the post-translation modification of Ras. Inhibitors of vascular growth factor receptor (bevacizumab and PTK787) and matrix metalloproteinase target the effects of the host environment. Cyclooxygenase-2 inhibitors in colorectal cancer and STI571 in GI stromal tumors represent novel therapies of interest for these specific GI cancers. Evidence suggests that novel agents can be administered alone or in combination with standard therapies with little additional toxicity. The results of ongoing and future research efforts will clarify the optimal use and survival benefit of targeted therapies for patients with GI malignancies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Schottenfeld D: Gastrointestinal cancer: epidemiology. In Gastrointestinal Oncology: Principles and Practice. Edited by Kelsen DP, Daly JM, Levin B, et al. Philadelphia: Lippincott, Williams & Wilkins; 2002:3–24.

    Google Scholar 

  2. Berlin J: New directions in the treatment of advanced colorectal cancer. Oncology (Huntingt) 2001, 15(Suppl 5):27–30.

    CAS  Google Scholar 

  3. Herbst RS, Shin DM: Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002, 94:1593–1611.

    Article  PubMed  CAS  Google Scholar 

  4. Mendelsohn J: The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 2001, 8:3–9. A comprehensive review of the rationale and application of EGFR blockade as an anticancer strategy, including insights into the mechanisms of C225.

    Article  PubMed  CAS  Google Scholar 

  5. Cunningham D, Humblet Y, Siena D, et al.: Cetuximab alone or in combination with irinotecan in patients with epidermal growth factor receptor positive, irinotecan- refractory metastatic colorectal cancer [abstract]. Proc Am Soc Clin Oncol 2003, 22:1012.

    Google Scholar 

  6. Schoffski P, Lutz M, Folprecht G, et al.: Cetuximab (C225) plus irinotecan (CPT-11) plus infusional 5FUfolinic acid (FA) is safe and active in metastatic colorectal cancer (MCRC), that expresses epidermal growth factor [abstract]. Proc Am Soc Clin Oncol 2002, 21:633.

    Google Scholar 

  7. Abbruzzese J, Rosenberg A, Xiong Q, et al.: Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer [abstract]. Proc Am Soc Clin Oncol 2001, 20:518.

    Google Scholar 

  8. Figlin R, Belldegrun A, Crawford J, et al.: ABX-EGF: a fully human anti-EGF receptor antibody in patients with advanced cancer. Phase I clinical results [abstract]. Proc Am Soc Clin Oncol 2001, 20:1102.

    Google Scholar 

  9. Ross JS, McKenna BJ: The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001, 19:554–568.

    Article  PubMed  CAS  Google Scholar 

  10. Buchler P, Reber HA, Buchler MC, et al.: Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin). J Gastrointest Surg 2001, 5:139–146.

    Article  PubMed  CAS  Google Scholar 

  11. Mann M, Sheng H, Shao J, et al.: Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 2001, 120:1713–1719.

    Article  PubMed  CAS  Google Scholar 

  12. Hwang JJ, Sinicrope F, Safran H, et al.: A phase II trial of irinotecan and trastuzumab (herceptin) in patients overexpressing Her-2/neu in metastatic colorectal cancer [abstract]. Proc Am Soc Clin Oncol 2001, 20:565.

    Google Scholar 

  13. de Bono JS, Hammond LA, Figueroa J, et al.: Phase I/II trial of Iressa (ZD1839) in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic colorectal cancer [abstract]. Br J Cancer 2002, 87(Suppl 1):56.

    Google Scholar 

  14. Cho CD, Fisher GA, Halsey J, et al.: A phase II study of getinib in combination with FOLFOX-4 in patients with unresectable or metastatic colorectal cancer [abstract]. Proc Am Soc Clin Oncol 2003, 22:1062.

    Google Scholar 

  15. Ranson M, Hammond LA, Ferry D, et al.: ZD1839, a selective oral epidermal growth factor receptortyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002, 20:2240–2250.

    Article  PubMed  CAS  Google Scholar 

  16. Herbst RS, Maddox AM, Rothenberg ML, et al.: Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002, 20:3815–3825.

    Article  PubMed  CAS  Google Scholar 

  17. Hidalgo M, Siu LL, Nemunaitis J, et al.: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001, 19:3267–3279.

    PubMed  CAS  Google Scholar 

  18. Adjei AA: Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001, 93:1062–1074. A landmark review detailing Ras signaling and targets for therapy.

    Article  PubMed  CAS  Google Scholar 

  19. Cunningham CC, Holmlund JT, Geary RS, et al.: A phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma. Cancer 2001, 92:1265–1271.

    Article  PubMed  CAS  Google Scholar 

  20. Burch PA, Alberts SA, Schroeder M, et al.: Gemcitabine and ISIS 2503 for patients with pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) phase II study [abstract]. Proc Am Soc Clin Oncol 2003, 22:1038.

    Google Scholar 

  21. Rowinsky EK, Windle JJ, {Pavon} {FnHoff} {GnDD}: Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol 1999, 17:3631–3652.

    PubMed  CAS  Google Scholar 

  22. de Bono JS, Rowinsky EK: Therapeutics targeting signal transduction for patients with colorectal carcinoma. Br Med Bull 2002, 64:227–254.

    Article  PubMed  Google Scholar 

  23. Du W, Prendergast GC: Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors. Cancer Res 1999, 59:5492–5496.

    PubMed  CAS  Google Scholar 

  24. End DW, Smets G, Todd AV, et al.: Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 2001, 61:131–137.

    PubMed  CAS  Google Scholar 

  25. Karp JE, Lancet JE, Kaufmann SH, et al.: Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical laboratory correlative trial. Blood 2001, 97:3361–3369. An important study with the most promising published clinical results for FTIs.

    Article  PubMed  CAS  Google Scholar 

  26. Crul M, de Klerk GJ, Swart M, et al.: Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2002, 20:2726–2735.

    Article  PubMed  CAS  Google Scholar 

  27. Punt CJ, van Maanen L, Bol CJ, et al.: Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors. Anticancer Drugs 2001, 12:193–197.

    Article  PubMed  CAS  Google Scholar 

  28. Zujewski J, Horak ID, Bol CJ, et al.: Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2000, 18:927–941.

    PubMed  CAS  Google Scholar 

  29. Cohen SJ, Ho L, Ranganathan S, et al.: Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol 2003, 21:1301–1306.

    Article  PubMed  CAS  Google Scholar 

  30. Patnaik A, Eckhardt SG, Izbicka E, et al.: A phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with gemcitabine [abstract]. Proc Am Soc Clin Oncol 2000, 19:5A.

    Google Scholar 

  31. Verweij J, Kehrer DF, Planting AS, et al.: Phase I trial of irinotecan in combination with the farnesyl transferase inhibitor R115777 [abstract]. Proc Am Soc Clin Oncol 2001, 20:319.

    Google Scholar 

  32. Verslype C, van Steenbergen W, Humblet Y, et al.: Phase I trial of 5-FU/LV in combination with the farnesyltransferase inhibitor R115777 [abstract]. Proc Am Soc Clin Oncol 2001, 20:681.

    Google Scholar 

  33. Holden SN, Eckhardt SG, Fisher S, et al.: A phase I pharmacokinetic and biological study of the farnesyl transferase inhibitor R115777 and capecitabine in patients with advanced solid malignancies [abstract]. Proc Am Soc Clin Oncol 2001, 20:319.

    Google Scholar 

  34. Cunningham D, de Gramont A, Schiethauer W, et al.: Randomized double-blind placebo-controlled trial of the farnesyltransferase inhibitor R115777 (Zarnestra) in advanced refractory colorectal cancer [abstract]. Proc Am Soc Clin Oncol 2002, 21:502.

    Google Scholar 

  35. van Cutsem E, Karasek P, Oettle H, et al.: Phase III trial comparing gemcitabine + R115777 versus gemcitabine + placebo in advanced pancreatic cancer [abstract]. Proc Am Soc Clin Oncol 2002, 21:517.

    Google Scholar 

  36. Adjei AA, Erlichman C, Davis JN, et al.: A phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res 2000, 60:1871–1877.

    PubMed  CAS  Google Scholar 

  37. Sharma S, Kemeny N, Kelsen DP, et al.: A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Ann Oncol 2002, 13:1067–1071.

    Article  PubMed  CAS  Google Scholar 

  38. Shi B, Yaremko B, Hajian G, et al.: The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother Pharmacol 2000, 46:387–393.

    Article  PubMed  CAS  Google Scholar 

  39. Pierson AS, Holden SN, Basche M, et al.: A phase I pharmacokinetic and biological study of the farnesyl transferase inhibitor sarasar (lonafarnib, SCH66336), cisplatin and gemcitabine in patients with advanced solid tumors [abstract]. Proc Am Soc Clin Oncol 2002, 21:365.

    Google Scholar 

  40. Lersch C, van Cutsem E, Amado R, et al.: Randomized phase II study of SCH 66336 and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas [abstract]. Proc Am Soc Clin Oncol 2001, 20:608.

    Google Scholar 

  41. Hurwitz HI, Amado R, Prager D, et al.: Phase I pharmacokinetic trial of the farnesyl transferase inhibitor SCH66336 plus gemcitabine in advanced cancers [abstract]. Proc Am Soc Clin Oncol 2000, 19:712.

    Google Scholar 

  42. Arii S, Mori A, Uchida S, et al.: Implication of vascular endothelial growth factor in the development and metastasis of human cancers. Hum Cell 1999, 12:25–30.

    PubMed  CAS  Google Scholar 

  43. Harada Y, Ogata Y, Shirouzu K: Expression of vascular endothelial growth factor and its receptor KDR (kinase domain-containing receptor)/Flk-1 (fetal liver kinase-1) as prognostic factors in human colorectal cancer. Int J Clin Oncol 2001, 6:221–228.

    Article  PubMed  CAS  Google Scholar 

  44. Presta LG, Chen H, O'Connor SJ, et al.: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57:4593–4599.

    PubMed  CAS  Google Scholar 

  45. Warren RS, Yuan H, Matli MR, et al.: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995, 95:1789–1797.

    Article  PubMed  CAS  Google Scholar 

  46. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al.: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003, 21:60–65.

    Article  PubMed  CAS  Google Scholar 

  47. Hurwitz HI, Fehrenbacher T, Cartwright J, et al.: Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer: results of a phase III trial of bevacizumab in combination with bolus IFL as first-line therapy in subjects with metastatic CRC [abstract]. Proc Am Soc Clin Oncol, 2003, 22:3646. The first clinical trial to demonstrate the survival efficacy of an antiangiogenic strategy in a solid tumor.

    Google Scholar 

  48. Britten CD, Rosen L, Kabbinavar F, et al.: Phase I trial of SU668, a small molecule receptor tyrosine kinase inhibitor, given twice daily in patients with advanced cancers [abstract]. Proc Am Soc Clin Oncol 2002, 21:1922.

    Google Scholar 

  49. Wood JM, Bold G, Buchdunger E, et al.: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000, 60:2178–2189.

    PubMed  CAS  Google Scholar 

  50. Thomas A, Morgan G, Drevs J, et al.: Pharmacodynamic results using dynamic contrast enhanced magnetic resonance imaging of two phase 1 studies of the VEGF inhibitor PTK787/ZK222584 in patients with liver metastases from colorectal cancer [abstract]. Proc Am Soc Clin Oncol 2001, 20:279.

    Google Scholar 

  51. McCawley LJ, Matrisian LM: Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today 2000, 6:149–156.

    Article  PubMed  CAS  Google Scholar 

  52. Bramhall SR, Rosemurgy A, Brown PD, et al.: Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001, 19:3447–3455.

    PubMed  CAS  Google Scholar 

  53. Bramhall SR, Hallissey MT, Whiting J, et al.: Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer 2002, 86:1864–1870.

    Article  PubMed  CAS  Google Scholar 

  54. King J, Zhao J, Clingan P, Morris D: Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side effects. Anticancer Res 2003, 23:639–645.

    PubMed  CAS  Google Scholar 

  55. Jacoby RF, Seibert K, Cole CE, et al.: The cyclooxygenase- 2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 2000, 60:5040–5044.

    PubMed  CAS  Google Scholar 

  56. Trifan OC, Durham WF, Salazar VS, et al.: Cyclooxygenase- 2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res 2002, 62:5778–5784.

    PubMed  CAS  Google Scholar 

  57. Sweeney C, Seitz D, Ansari R, et al.: Phase II trial of irinotecan, 5-fluorouracil, leucovorin, celecoxib and glutamine as first-line therapy for advanced colorectal cancer: a Hoosier Oncology Group Study [abstract]. Proc Am Soc Clin Oncol 2002, 21:2364.

    Google Scholar 

  58. Lin E, Morris J, Chau N, et al.: Celecoxib attenuated capecitabine induced hand-and-foot syndrome and diarrhea and improved time to tumor progression in metastatic colorectal cancer [abstract]. Proc Am Soc Clin Oncol 2002, 21:2235.

    Google Scholar 

  59. Blanke C, Benson AB 3rd, Dragovich T, et al.: A phase II trial of celecoxib (CX), irinotecan (I), 5-fluorouracil (FU), and leucovorin (LCV) in patients (PTS) with unresectable or metastatic colorectal cancer (CRC). Paper presented at the 38th Annual American Society of Clinical Oncologists Meeting. Orlando, FL; May 19, 2002.

  60. Druker BJ: Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy. Eur J Cancer 2002, 38(Suppl 5):S70-S76.

    Article  PubMed  Google Scholar 

  61. Heinrich MC, Griffith DJ, Druker BJ, et al.: Inhibition of c-kit receptor tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitor. Blood 2000, 96:925–932.

    PubMed  CAS  Google Scholar 

  62. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al.: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001, 344:1052–1056. An important trial reporting a dramatic response to STI571 in patients with refractory GIST.

    Article  PubMed  CAS  Google Scholar 

  63. Huang SM, Harari PM: Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs 1999, 17:259–269.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, The University of North Carolina at Chapel Hill, CB# 7305, 3009 Old Clinic Building, 27599, Chapel Hill, NC, USA

    Richard M. Goldberg MD

Authors
  1. Sharlene Gill MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rebecca R. Thomas MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard M. Goldberg MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gill, S., Thomas, R.R. & Goldberg, R.M. New targeted therapies in gastrointestinal cancers. Curr. Treat. Options in Oncol. 4, 393–403 (2003). https://doi.org/10.1007/s11864-003-0040-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-003-0040-9

Keywords

Search

Navigation